Braftovi + Erbitux ± Mektovi: A Market Perspective on Targeted Cancer Therapies to 2032
Overview of Braftovi + Erbitux ± Mektovi Combination Therapy The combination therapy of Braftovi (encorafenib), Erbitux (cetuximab), and optionally Mektovi (binimetinib) has emerged as an essential treatment option for certain cancer types, particularly metastatic colorectal cancer (mCRC) with the BRAFV600E mutation. This targeted therapy works